The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns.

STS designed these new mobile-friendly resources with updated data and modern surgical techniques in mind.

Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice. 

"We are failing to rescue women after high-risk surgery," one researcher said after reviewing years of Medicare data. 

Despite these incidents, CT continues to be the preferred imaging technology for patients with implantable or wearable medical devices.

Most cardiac devices do not fit young children, making it especially important for growth in pediatric cardiology to continue. The FDA helped fund a contest aimed at identifying new devices that show a ton of potential. 

Dynocardia has now received nearly $5.1 million in funding from the NHLBI to help speed commercializing its wrist-worn monitor to avoid the need for invasive catheter BP monitoring.

The objective of the AHA scientific statement is to review the available evidence on for better management of cardiac arrhythmias from COVID causes that are still encountered on a regular basis.